Program
ravagalimab
Also written as “Ravagalimab”, “Ravagalimab 600 mg” and “Ravagalimab 300 mg”.
Its studies are mostly in Arthritis, Rheumatoid · Colitis, Ulcerative · Sjogren's Syndrome, led by AbbVie.
Furthest: phase 2, since Oct 2, 20184 company-led studies, 1 open or runningNext primary completion: Feb 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 41 open or running | phase 2since Oct 2, 2018 | Oct 2, 2018 | Feb 2027phase 2 · NCT06972446 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 2, 2018First study: phase 2 study in Colitis, UlcerativeFirst studyNCT03695185 · 42 enrolled · United States, Canada, France and more
- Feb 6, 2020Phase 2 study in Sjogren's SyndromeNCT05217472 · Netherlands
- May 3, 2024Phase 1 study in Healthy VolunteersNCT06402513 · 12 enrolled · United States
- May 7, 2025Phase 2 study in Arthritis, RheumatoidNCT06972446 · 180 planned · United States, Canada, Czechia and more
Ahead
- Feb 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT06972446
TargetBeta
CD40LG →read by rule
“CD40 ligand antagonist”ChEMBL 37, by rule
Other programs on CD40LG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| frexalimab | Sanofi | phase 3 | 11 |
| dazodalibeprule | Amgen | phase 3 | 9 |
| dapirolizumab pegolrule | UCB | phase 3 | 8 |
| tegoprubartrule | eledon-pharmaceuticals | phase 3 | 8 |
| OPT101rule | op-t-llc | phase 2 | 4 |
| TNX-1500rule | Tonix Pharmaceuticals | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06972446Arthritis, Rheumatoid · United States, Canada, Czechia and more | 2 | Recruiting | Feb 2027 | 180 |
| NCT06402513Healthy Volunteers · United States | 1 | Completed | Oct 8, 2024 | 12 |
| NCT05217472Sjogren's Syndrome · Netherlands | 2 | Withdrawn | Apr 15, 2022 | 0 |
| NCT03695185Colitis, Ulcerative · United States, Canada, France and more | 2 | Completed | Apr 5, 2021 | 42 |
How it is read
Names in the registry
- “Ravagalimab”, 3 entries
- “Ravagalimab 600 mg”, 1 entry
- “Ravagalimab 300 mg”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
- Colitis, Ulcerative, 1 study
- Sjogren's Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.